Longevity.Technology UNLOCKED

Longevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living. 🎙 Mondays: In-depth conversations with scientists, founders, investors, operators, and elite performers shaping the longevity ecosystem.🧠 Fridays: A sharp weekly round-up of the biggest stories, trends, and insights from across the longevity space.If you’re curious about the future of health, performance, and lifespan, this is where it gets UNLOCKED.

Longevity.Technology UNLOCKED is a health podcast hosted by Longevity.Technology, with 72 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Longevity.Technology hosts Longevity.Technology UNLOCKED, a health show with 72 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Longevity.Technology UNLOCKED

  Can You Make Your Brain 5 Years Younger?

  Sep 14, 202648 min

  Guests: Paola Telfer Founder and CEO of Sens.ai LinkedIn: www.linkedin.com/in/paolatelfer/ Website: sens.ai/ Eric Verdin, MD President and CEO of the Buck Institute for Research on Aging LinkedIn: www.linkedin.com/in/eric-verdin-md/ Website: www.buckinstitute.org/ ---------- What if we could track brain aging through function, not just structure? Phil Newman sits down with Paola Telfer, founder and CEO of Sens.ai, and Eric Verdin, president and CEO of the Buck Institute for Research on Aging, to explore BrainYears™, a functional brain age clock designed to measure how the brain performs as it ages. Together they explain how 643 EEG, response and performance variables were analyzed using machine learning to build the BrainYears™ model. They discuss why brain function could complement MRI, retinal, proteomic and epigenetic clocks, and how data collected from people aged 13 to their late 80s helped build the model. The conversation also examines a reported 5.18-year reduction in BrainYears™ following a two-month intervention, while stressing that this early finding still requires prospective, placebo-controlled validation. They also explore neurofeedback, HRV biofeedback and transcranial photobiomodulation, the potential role of BrainYears™ in clinical practice, and Eric’s vision for a scientifically rigorous space between conventional medicine and consumer wellness. In this episode, you’ll learn: Why functional brain aging may be a missing dimension in current aging clocks How 643 EEG, response and performance variables were narrowed down using machine learning to create the BrainYears™ model Why tracking trajectory over time may be more informative than a single biological age score What the early intervention data showing a reported 5.18-year BrainYears™ reduction actually tells us Why future validation needs to compare BrainYears™ with MRI-based clocks, proteomics and other measures of brain aging If you want to understand how brain aging could become measurable, trackable and potentially modifiable earlier in life, this episode explores the science, technology and validation challenges shaping that future. Subscribe for weekly episodes exploring longevity science, preventative medicine and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY

  ListenShow Notes
• 

  Longevity.Technology UNLOCKED

  The Smart Ring Accuracy Crisis | Longevity News Roundup — Week 37, 2026

  Sep 11, 202617 min

  In this week’s Longevity News Roundup, Phil Newman examines Oura’s IPO and sleep suit, movement context in dementia, dog gene therapy, Rentosertib biological clocks, and women's health. ŌURA filed for a $16 billion IPO on Nasdaq under ticker Oura, seeking to raise up to $3 billion. Simultaneously, the smart ring company is defending its sleep stage tracking accuracy in a California class action lawsuit alleging its metrics are no better than a coin flip. A 74-study review of 4.2 million people showed leisure movement lowered dementia risk by 24%, while physically demanding jobs increased risk by 20%. This highlights how movement context and recovery matter far more than basic step counts. GenFlow Biosciences reported that its SLAB trial testing SIRT6 gene therapy in 24 aged beagles met its primary endpoint. Treated dogs demonstrated reduced biological age on the Grim methylation clock alongside secondary functional gains. Insilico Medicine published a Phase 2a trial analysis revealing its AI-designed IPF drug Rentosertib reduced predicted biological age. Across six proteomic clocks, patients taking 30 mg twice daily showed three to four years of age reduction. Biograph launched a dedicated women's preventative health program integrated into its concierge membership tiers. The program combines hormone testing, personalized risk assessments, and life-stage care spanning perimenopause, menopause, and cardiovascular health. ---------- News & References: ‘Biograph builds dedicated women’s preventive health arm → https://longevity.technology/news/biograph-builds-dedicated-womens-preventive-health-arm/ Rentosertib puts aging clocks to the clinical test → https://longevity.technology/news/rentosertib-puts-aging-clocks-to-the-clinical-test/ Genflow Biosciences trial meets primary endpoint in aged dogs → https://longevity.technology/news/genflow-biosciences-trial-meets-primary-endpoint-in-aged-dogs/ Study shows the way you move matters more than how often → https://longevity.technology/news/study-shows-the-way-you-move-matters-more-than-how-often/ Smart ring maker Oura prepares for US IPO at up to $3b raise → https://longevity.technology/news/smart-ring-maker-oura-prepares-for-u-s-ipo-at-up-to-3b-raise/ ŌURA defends its sleep science amid class-action lawsuit → https://longevity.technology/news/oura-defends-its-sleep-science-amid-class-action-lawsuit/ ---------- Host:Phil Newman: https://qrco.de/bgXpNY

  ListenShow Notes
• 

  Longevity.Technology UNLOCKED

  Will AI Make Death Optional?

  Sep 7, 202617 min

  What would have to be true for AI to genuinely change the trajectory of human aging? The answer is more complicated than simply discovering an “anti-aging drug.” AI is already compressing parts of drug discovery, with one AI-designed candidate reaching Phase 2 trials in under 30 months, while new biological aging clocks could allow researchers to measure changes in months rather than decades. But aging is not a single disease. It involves interconnected processes including cellular senescence, mitochondrial dysfunction, immune changes, DNA damage, and loss of biological coordination. AI can search faster, but it cannot remove the underlying biological trade-offs or eliminate the need for long-term human safety data. Phil examines what longevity escape velocity actually means, why skepticism remains essential, and whether AI can accelerate progress quickly enough to matter within our own lifetimes. In this episode, you’ll learn: How AI is compressing drug discovery timelines and what that could mean for longevity research. Why biological aging clocks could become critical tools for testing interventions faster. Why aging is fundamentally more complex than targeting a single disease pathway. How cellular reprogramming illustrates both the promise and risks of manipulating aging biology. Why progression from Phase 1 to Phase 2 may be a more useful scorecard than predictions about longevity escape velocity. If you want to understand what AI can realistically change about the pace of longevity research, this episode connects faster drug discovery and biological aging measurement with the deeper challenges of intervening in a complex, interconnected aging process. It explores where the science is genuinely moving forward, where the biggest limitations remain, and what could determine whether today’s advances translate into meaningful healthspan gains. Subscribe for more Longevity Bites, where Phil Newman breaks down the science, ideas, and emerging technologies shaping the future of human longevity ---------- Host: Phil Newman: https://qrco.de/bgXpNY

  ListenShow Notes
• 

  Longevity.Technology UNLOCKED

  The $820 Million Bet to Transform Hair Loss Treatment | Longevity News Roundup - Week 36, 2026

  Sep 4, 202618 min

  In this week’s Longevity News Roundup, Phil Newman examines the developments reshaping longevity and healthspan, from a major biotech investment in hair loss to AI-driven drug repurposing, the industry’s communication challenge, biological-age testing at population scale, and the push to manufacture regenerative cell therapies in the US. Veradermics has built an $820 million war chest to advance VDPHL01, an extended-release oral formulation of minoxidil for male and female pattern hair loss. Phase 3 data for men are expected in the second half of 2026, with topline results from the women’s Phase 2/3 trial expected in the first half of 2027. THPharm and Insilico Medicine are using AI to investigate new applications for THP-001, already in global Phase 3 trials. PandaOmics is analysing 16 datasets covering 269 samples to explore potential applications in heart failure, fatty liver disease and obesity. HEALTH’s new Longevity Insights Report, based on responses from 1,000 Americans, suggests consumers are more interested in staying healthy, energetic and independent than simply extending lifespan. Humanity and Quest Diagnostics are making biological-age analysis available through Quest’s direct-to-consumer testing platform for $29. The bigger opportunity may be turning biological age into a repeatable health metric that encourages prevention and measurable improvements over time. Celularity and MuseCell Innovations are establishing US manufacturing for Dezawa MuseCells, alongside derived products including MuseExosomes and MuseSecretome. The collaboration addresses one of regenerative medicine’s biggest challenges: producing specialist cell therapies consistently and at scale. News & References: ‘Veradermics builds $820m war chest for oral hair loss pill → https://longevity.technology/news/veradermics-builds-820m-war-chest-for-oral-hair-loss-pill/ AI hunts new uses for Phase 3 metabolic drug → https://longevity.technology/news/ai-hunts-new-uses-for-phase-3-metabolic-drug/ New survey reveals what Americans really want from longevity → https://longevity.technology/news/new-survey-reveals-what-americans-really-want-from-longevity/ Quest, Humanity bring biological age test to 2,000 US locations→ https://longevity.technology/news/quest-humanity-bring-biological-age-test-to-2000-us-locations/ Celularity, MuseCell Innovations to build US Dezawa MuseCell plant → https://longevity.technology/news/celularity-musecell-innovations-to-build-us-dezawa-musecell-plant/ ---------- Host:Phil Newman: https://qrco.de/bgXpNY

  ListenShow Notes
• 

  Longevity.Technology UNLOCKED

  Are Longevity Clinics Actually Evidence-Based?

  Aug 31, 202652 min

  Guest: Joanna Bensz Founder & CEO of Longevity Center and Longevity Academy LinkedIn: https://www.linkedin.com/in/joanna-bensz-205b315/ Website: https://longevity-academy.com /, https://longevity-center.eu/ ---------- What happens when longevity becomes a global industry before the medical system has agreed on what good longevity medicine actually looks like? Phil Newman sits down with Joanna Bensz, entrepreneur, founder of the International Institute of Longevity, Longevity Academy and Round Table of Longevity Clinics, to explore how a rapidly expanding sector can develop credible standards while keeping pace with commercialization. They discuss the growth of longevity clinics, from premium destinations and telehealth platforms to sports centres and preventive health providers, and why Joanna estimates that only around 20% of the clinics she knows genuinely focus on diagnostics and interventions. The conversation examines peptides, biological-age testing, clinical education and the need for protocols that connect biomarkers with appropriate interventions rather than simply adding more treatments. Joanna explains how Longevity Academy evolved from an internal doctor-training programme into an educational platform for clinicians, drawing on real-world clinic experience, biomarkers, testing and treatment decisions. The episode goes beyond the clinic itself, examining the growing role of sports centres, retreats, AI, mental health, nervous-system regulation, nutrition and family health. Joanna argues that longevity should not be reduced to peptides or expensive interventions, but should include the everyday environments and behaviours that shape health across the lifespan. In this episode, you’ll learn: Why rapid commercialization could outpace the development of clinical standards Why Joanna estimates only around 20% of longevity clinics genuinely focus on diagnostics and interventions How Longevity Academy is helping doctors bridge gaps in conventional medical education Why peptides illustrate the regulatory differences between the US and Europe Why longevity clinics need doctors, nutritionists, psychologists, coaches and other specialists working together - How biomarkers can be used to track changes before and after interventions Ultimately, this episode asks whether longevity medicine can become a credible part of healthcare without losing scientific and clinical rigor as the market scales. For Joanna, the path forward involves better education, clearer standards, measurable outcomes, collaboration and a more integrated approach to health that extends beyond the traditional doctor-patient relationship. Subscribe for weekly episodes exploring longevity science, preventative medicine, healthcare innovation and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY

  ListenShow Notes

Recent guests on Longevity.Technology UNLOCKED. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.